Why Has Stifel Given Ultragenyx Pharma (NASDAQ:RARE) a $125 Price Target
New York: Ultragenyx Pharma (NASDAQ:RARE) coverage has been initiated with a key ‘Buy’ rating as well as a $125 target price per share at Stifel. The target price per share by Stifel may mean upside of 27.14% from the current price.
From a total of 5 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) stock, 4 rate it a ”Buy”, 1 a “Sell”, and 0 a ”Hold”. This means that 80% of the ratings are positive. The highest target price is $126 while the lowest target price is $108. The mean of all analyst targets is $118.20 with a 18.02% above today’s ($100.15) stock price. Ultragenyx Pharmaceutical Inc was the topic of 8 analyst reports since July 27, 2015 according to the firm StockzIntelligence Inc. Jefferies initiated shares on October 23 with “Buy” rating. Raymond James initiated RARE stock in a recent report from September 1 with “Outperform” rating. Finally, SunTrust maintained the stock with “Buy” rating in a report issued on a July 13.
Approximately shares of stock traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 65.24% since April 28, 2015 and is uptrending. It has outperformed by 66.87% the S&P500.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $3.89 billion. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It currently has negative earnings. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.
According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.” Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical Inc (RARE)